Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAptamer Group Regulatory News (APTA)

Share Price Information for Aptamer Group (APTA)

Share Price is delayed by 15 minutes
Get Live Data
0.525    -0.025 (-4.55%)
Bid:
0.50
Ask:
0.55
Spread: 0.05 (10.00%)
Market Cap: £18.14m
APTA Live PriceLast checked at - London Stock Exchange

Intraday Aptamer Group Share Chart

TR-1

15 Aug 2023 17:40

RNS Number : 4198J
Aptamer Group PLC
15 August 2023
Ā 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BNRRP542

Issuer Name

APTAMER GROUP PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An event changing the breakdown of voting rights

3. Details of person subject to the notification obligation

Name

Amati Global Investors Limited

City of registered office (if applicable)

Edinburgh

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Name

City of registered office

Country of registered office

Amati AIM VCT plc

London

United Kingdom

5. Date on which the threshold was crossed or reached

04-Aug-2023

6. Date on which Issuer notified

08-Aug-2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

3.950000

0.000000

3.950000

3138042

Position of previous notification (if applicable)

4.550000

0.000000

4.550000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BNRRP542

3138042

3.950000

Sub Total 8.A

3138042

3.950000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Ā 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Ā 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Ā 

10. In case of proxy voting

Name of the proxy holder

Ā 

The number and % of voting rights held

Ā 

The date until which the voting rights will be held

Ā 

11. Additional Information

Ā 

12. Date of Completion

08-Aug-2023

13. Place Of Completion

Edinburgh, UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Ā 
END
Ā 
Ā 
HOLNKPBNABKDOFD
Date   Source Headline
13th Apr 20261:08 pmRNSResult of General Meeting
31st Mar 20267:00 amRNSResult of Retail Offer and Posting of Notice of GM
26th Mar 20267:05 amRNSRetail Offer to raise up to £0.5 million
26th Mar 20267:00 amRNSResults of Placing
25th Mar 20267:10 amRNSInterim Results and Notice of Investor Webinar
25th Mar 20267:00 amRNSProposed Placing, Subscription and Retail Offer
18th Mar 20267:00 amRNSLaunch of targeted radiopharmaceutical programme
10th Mar 20263:26 pmRNSBlock Listing Interim Review
17th Feb 20267:00 amRNS-RTechnical Feasibility for Pathogen Detector
11th Feb 20267:00 amRNSOptimer® Technology in Launched Library Prep Kit
29th Jan 20267:00 amRNSContract wins and first cash licensing receipts
7th Jan 20264:04 pmRNSTrading update - Media comment and speculation
7th Jan 20267:00 amRNSHalf Year Trading Update
23rd Dec 20257:00 amRNSAptamer signs licensing agreement with Alphazyme
23rd Dec 20257:00 amRNSAptamer signs licensing agreement with Alphazyme
16th Dec 202510:34 amRNSLicensing agreement with Twist Bioscience
27th Nov 20251:01 pmRNSResults of 2025 Annual General Meeting
27th Nov 20257:00 amRNSAGM Statement
14th Nov 20257:00 amRNSStrong contract wins build commercial momentum
4th Nov 20257:00 amRNSNew contract with top five pharma company
3rd Nov 20257:00 amRNSPosting of Annual Report and Notice of AGM
14th Oct 20257:00 amRNSFull Year Results for the 12mths to 30 June 2025
13th Oct 20257:00 amRNSNew contract with top 10 pharma
10th Oct 20257:00 amRNSNotice of Results, Analyst & Investor Presentation
8th Oct 20257:00 amRNSMajor top 3 global pharma contract win
26th Sep 20257:00 amRNS-RInvestor Event and Presentation
11th Sep 20257:00 amRNS-RNew contract with Metir plc
9th Sep 20257:00 amRNSNotification of dealings by a director/PDMR
2nd Sep 20257:00 amRNSTherapeutic development agreement with Invizius
28th Aug 20257:00 amRNSBlock Listing Interim Review
27th Aug 20257:00 amRNSBiomarker Discovery Service Launch
22nd Aug 20257:00 amRNSUpdate on licensing and development progress
19th Aug 20257:00 amRNSExercise of warrants
18th Aug 20253:44 pmRNSHolding(s) in Company
18th Aug 20257:00 amRNSContract extension with global pharma partner
8th Aug 20257:00 amRNS-RInvestor Technical Webinar
7th Aug 20255:24 pmRNSHolding(s) in Company
5th Aug 20258:05 amRNSHolding(s) in Company
31st Jul 20251:29 pmRNS-RInvestor Webinar
31st Jul 20257:00 amRNSTrading Update
28th Jul 202512:25 pmRNSHolding(s) in Company
24th Jul 202511:48 amRNSResult of General Meeting
21st Jul 20257:00 amRNSAdditional work commissioned by Unilever
18th Jul 20257:00 amRNSIssue of Equity in lieu of Non-Exec Director Fees
9th Jul 20252:53 pmRNSHolding(s) in Company
8th Jul 20257:00 amRNSPosting of Circular and Notice of General Meeting
4th Jul 20257:00 amRNSPlacing to raise £2.0 million
30th Jun 20257:00 amRNSLiver fibrosis breakthrough with Optimer® platform
25th Jun 20257:00 amRNSAgreement with global life sciences leader
30th May 20257:00 amRNSUnilever second Optimer development programme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.